摘要
瑞舒伐他汀作为目前最新且最具潜力的一类他汀类药物,与同类药物相比能更有效地降低血浆中低密度脂蛋白,同时降低胆固醇、载脂蛋白B,并且显著增加高密度脂蛋白胆固醇。不仅如此,在心血管疾病的二级预防和一级预防中,有研究显示瑞舒伐他汀的长期使用能够逆转动脉粥样斑块负荷,减少心血管事件发生率和死亡率,降低动脉粥样硬化炎性指标,使存在不同程度心血管疾病风险的患者在其调脂治疗中获益。本文就瑞舒伐他汀的临床研究进展做一综述。
Rosuvastain is the latest and most potent statin currently. It has the greatest efficacy on reduction of low-density lipoprotein cholesterol, triglycerides cholesterol, and apolipoprotein B compared with all other available statins. It also provides a significant increase in high-density lipoprotein cholesterol. Moreover, in the primary and secondary prevention on cardiovascular disease （CVD）, using rosuvastain for a long time can make a regression of the atherosclerotic burden, reduce morbidity and mortality, and decrease the inflammatory marker in atherosclerosis which can make the patients with high or low risk of CVD get great benefits from lipid-lowering therapy. The advancement of rosuvastain in current clinic researches are reviewed in this article.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2010年第11期813-816,共4页
Chinese Journal of New Drugs and Clinical Remedies
